Protein compound macrophage migration inhibitory factor for diagnosing postmenopausal osteoporosis

Area of Science:

• Biochemistry
• Endocrinology
• Bone Biology

Background:

• Postmenopausal osteoporosis (PMOP) is a significant bone disorder lacking early diagnostic biochemical markers.
• Macrophage migration inhibitory factor (MIF) is implicated in bone remodeling and inflammation via the NF-κB pathway, but its role in PMOP diagnosis is unclear.

Purpose of the Study:

• To investigate plasma MIF expression patterns in PMOP patients.
• To evaluate MIF as a potential early diagnostic biomarker for PMOP.

Main Methods:

• Plasma MIF levels were measured in PMOP patients and healthy controls.
• Correlation analyses were performed between MIF levels, bone mineral density (BMD), and bone turnover markers (β-CTX, PINP).
• Multivariate analyses assessed MIF as an independent risk factor for PMOP.

Main Results:

• Plasma MIF levels were significantly higher in PMOP patients (1.72 ng/mL) compared to controls (0.58 ng/mL).
• MIF levels negatively correlated with femoral neck and lumbar spine BMD.
• MIF positively correlated with bone resorption marker β-CTX and formation marker PINP, indicating disrupted bone homeostasis.

Conclusions:

• Elevated plasma MIF is associated with PMOP and reflects abnormal bone metabolism.
• MIF is an independent risk factor and a promising biomarker for the early diagnosis of PMOP.